Top 50 Biotechnology Startup Investors in Denmark (October 2026)
For AI agents: Short investor table (Markdown), Detailed investor list (Markdown)
| Investor | Relevant Deals | Geography | Stage | Focus | Round Size |
|---|---|---|---|---|---|
|
Novo Holdings
VC Fund
|
35 | United States, Denmark, United Kingdom | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $9.5M–$135M |
|
BioInnovation Institute
VC Fund
|
28 | Denmark, Germany, Switzerland | Convertible Note, Pre-Seed, Seed | Biotechnology, Medical, Health Care | $495k–$5.2M |
|
Vaekstfonden
VC Fund
|
20 | Denmark, United States, United Kingdom | Seed, Venture - Series Unknown | Software, Information Technology, SaaS | $899k–$23M |
|
Export and Investment Fund
VC Fund
|
18 | Denmark, United States, Norway | Seed, Series A, Pre-Seed | Software, Biotechnology, Health Care | $395k–$84M |
|
Seed Capital
VC Fund
|
11 | Denmark, United States, United Kingdom | Seed, Venture - Series Unknown | Software, Health Care, Information Technology | $508k–$5.5M |
|
Sunstone Life Science Ventures
VC Fund
|
7 | Denmark, Sweden, Switzerland | Series A, Series B | Biotechnology, Health Care, Medical | $5.5M–$61M |
|
PSV
VC Fund
|
7 | Denmark, United States, Sweden | Seed, Pre-Seed, Venture - Series Unknown | Software, Information Technology, Artificial Intelligence | $307k–$4.6M |
|
Nordic Foodtech VC
VC Fund
|
6 | Finland, Denmark, Sweden | Seed, Pre-Seed, Series A | Biotechnology, Food and Beverage, Life Science | $610k–$18M |
|
Gilde Healthcare
VC Fund
|
6 | United States, The Netherlands, Germany | Series B, Series C, Series A | Health Care, Biotechnology, Medical | $9.5M–$135M |
|
Oskare Capital
VC Fund
|
6 | Italy, Denmark, United Kingdom | Seed, Series A, Pre-Seed | Health Care, Biotechnology, Medical | $1.2M–$5.9M |
|
RA Capital Management
VC Fund
|
5 | United States, United Kingdom, China | Series B, Post-IPO Equity, Series A | Biotechnology, Health Care, Therapeutics | $20M–$275M |
|
2xN
VC Fund
|
5 | Denmark, United States, United Kingdom | Seed, Series A, Series B | Software, Information Technology, Quantum Computing | $1.9M–$125M |
|
West Hill Capital
VC Fund
|
5 | United Kingdom, Denmark, Germany | Venture - Series Unknown, Series A, Seed | Health Care, Information Technology, Software | $1.8M–$15M |
|
DSM Venturing
VC Fund
|
4 | United States, Canada, Israel | Series A, Series B | Health Care, Biotechnology, Manufacturing | $3.5M–$32M |
|
PINC
VC Fund
|
4 | Sweden, Denmark, United Kingdom | Seed, Pre-Seed, Series A | Biotechnology, Food and Beverage, Agriculture | $89k–$7.2M |
|
VF Venture
VC Fund
|
4 | Denmark, United Kingdom, Iceland | Seed, Series A, Venture - Series Unknown | Software, Biotechnology, Medical Device | $1.2M–$31M |
|
EIR Ventures
VC Fund
|
4 | Denmark, Sweden, United States | Series A, Seed | Biotechnology, Health Care, Therapeutics | $20M–$73M |
|
Ysios Capital
VC Fund
|
4 | Spain, United States, Switzerland | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $3.8M–$135M |
|
ACME Capital
VC Fund
|
4 | United States, Denmark, Canada | Seed, Series A, Series B | Software, Health Care, Artificial Intelligence | $1.6M–$65M |
|
Per Falholt
Angel
|
4 | Denmark | Pre-Seed, Series A, Seed | Biotechnology, Robotics, Biopharma | $5.9M–$20M |
|
Atlantic
VC Fund
|
4 | Germany, Switzerland, United States | Seed, Series A, Pre-Seed | Software, Health Care, Artificial Intelligence | $850k–$30M |
|
HealthCap
VC Fund
|
4 | United States, Sweden, France | Series B, Series A | Biotechnology, Health Care, Medical | $6M–$92M |
|
Karolinska
VC Fund
|
3 | Sweden, Denmark, United States | Venture - Series Unknown, Seed | Biotechnology, Health Care, Pharmaceutical | $3.2M–$10M |
|
Nicholas Francis
Angel
|
3 | Denmark, United States | Seed, Series A | SaaS, Robotics, Software | $983k–$8.1M |
|
Innovation Fund Denmark
VC Fund
|
3 | Denmark, United States | Grant, Pre-Seed, Seed | Software, Biotechnology, SaaS | $35k–$2.1M |
|
Blue Horizon Corporation
VC Fund
|
3 | United States, United Kingdom, Germany | Seed, Series A, Pre-Seed | Food and Beverage, Food Processing, Biotechnology | $450k–$40M |
|
Thia Ventures
VC Fund
|
3 | United States, France, Denmark | Series A, Seed, Pre-Seed | Biotechnology, Health Care, Manufacturing | $3.4M–$48M |
|
NOON Ventures
VC Fund
|
3 | Denmark | Seed, Series A | Biotechnology, AgTech, Farming | $4.3M–$8.8M |
|
HTGF (High-Tech Gruenderfonds)
VC Fund
|
3 | Germany, Switzerland, United States | Seed, Series A, Pre-Seed | Software, Biotechnology, Information Technology | $790k–$31M |
|
Omega Funds
VC Fund
|
3 | United States, Switzerland, United Kingdom | Series A, Series B, Series C | Biotechnology, Health Care, Therapeutics | $14M–$208M |
|
Bioqube Ventures
VC Fund
|
3 | United States, France, Norway | Seed, Series A, Series B | Biotechnology, Therapeutics, Life Science | $4M–$108M |
|
Dawn Biopharma
VC Fund
|
3 | United States, Denmark, France | Series A, Seed, Series B | Biotechnology, Health Care, Therapeutics | $15M–$165M |
|
Sofinnova Partners
VC Fund
|
3 | France, United States, United Kingdom | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $7M–$105M |
|
Ugly Duckling Ventures
VC Fund
|
3 | Denmark, Sweden, Finland | Seed, Pre-Seed, Venture - Series Unknown | Software, Artificial Intelligence, Information Technology | $917k–$7.5M |
|
Lundbeckfonden Ventures
VC Fund
|
3 | United States, Denmark, United Kingdom | Series B, Series A, Series C | Biotechnology, Health Care, Therapeutics | $10M–$95M |
|
Unconventional Ventures
VC Fund
|
3 | Sweden, Denmark, United Kingdom | Seed, Pre-Seed, Series A | Health Care, Software, Wellness | $1M–$18M |
|
The Footprint Firm
VC Fund
|
3 | Denmark, Spain, Norway | Seed, Pre-Seed, Series A | Software, Renewable Energy, Energy Management | $863k–$18M |
|
Steen Riisgaard
Angel
|
2 | Denmark | Pre-Seed | Life Science, Therapeutics, Biotechnology | |
|
M Ventures
VC Fund
|
2 | United States, United Kingdom, Switzerland | Series A, Series B, Seed | Biotechnology, Health Care, Therapeutics | $2.4M–$100M |
|
SR One
VC Fund
|
2 | United States, United Kingdom, Canada | Series A, Series B, Series C | Biotechnology, Health Care, Therapeutics | $3.7M–$175M |
|
CAPNOVA
VC Fund
|
2 | Denmark, United States, India | Seed, Pre-Seed | Software, Information Technology, B2B | $147k–$2.4M |
|
Northzone
VC Fund
|
2 | United States, Sweden, United Kingdom | Series A, Series B, Seed | Software, Artificial Intelligence, FinTech | $2.5M–$100M |
|
Nina Capital
VC Fund
|
2 | United States, United Kingdom, Germany | Seed, Pre-Seed, Series A | Health Care, Artificial Intelligence, Software | $529k–$21M |
|
Balderton Capital
VC Fund
|
2 | United Kingdom, United States, Germany | Series A, Series B, Series C | Software, Artificial Intelligence, Financial Services | $5M–$160M |
|
Aescap Venture
VC Fund
|
2 | Switzerland, United Kingdom, The Netherlands | Series B, Series A, Series C | Biotechnology, Pharmaceutical, Health Diagnostics | $1.5M–$33M |
|
FundersClub
VC Fund
|
2 | United States, Canada, India | Seed, Series A, Pre-Seed | Software, Artificial Intelligence, SaaS | $125k–$23M |
|
Nordic Alpha Partners
VC Fund
|
2 | Denmark, Germany, Sweden | Venture - Series Unknown, Seed | Energy, Energy Storage, Renewable Energy | $3M–$9.8M |
|
The Yield Lab Europe
VC Fund
|
2 | Ireland, France, United Kingdom | Seed, Series A, Venture - Series Unknown | AgTech, Agriculture, Biotechnology | $605k–$10M |
|
byFounders
VC Fund
|
2 | Denmark, United States, Sweden | Seed, Pre-Seed, Series A | Software, Artificial Intelligence, SaaS | $750k–$65M |
|
Giampaolo Cagnin
Angel
|
2 | Italy, Denmark | Seed, Pre-Seed | Chemical, Biotechnology, Food and Beverage | $4.9M–$7.6M |
| Access all 360 investors in Denmark Biotechnology startups. | |||||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Investor list
Novo Holdings is a world-leading life science investor with a focus on creating long-term value.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: United States, Denmark, United Kingdom
Investor stats
- Total investments: 407
- Round size: Series A $9.5M–$133M; Series B $15M–$135M; Series C $30M–$118M
- Lead/follow: 40% lead, 60% follow
- Last fund: May invest from a new fund soon — raised $165M in 2018
Portfolio highlights
- IVERIC bio — IVERIC bio is a science-driven biopharmaceutical company focused on the discovery and development of novel treatment options for retinal diseases with significant unmet medical needs. The Company is currently developing both therapeutic product candidates for age-related retinal diseases and gene therapy product candidates for orphan inheritedretinal diseases.
- Windward Bio — Windward Bio is a clinical-stage, drug development company committed to improving outcomes for people living with serious immunological diseases.
- SCHOTT Poonawalla — SCHOTT Poonawalla is a manufacturer of pharmaceutical containers, made of neutral glass tubing. The company provides parenteral packaging systems crafted from tubular glass, serving the pharmaceutical industry with a broad range of products including vials, pre-fillable syringes, ampoules, and cartridges.
BioInnovation Institute is a biotechnology startup that offers entrepreneurs and researchers in life science. Early-stage life science start-ups are supported with up to 10 million DKK in funding, business acceleration, network, labs, and office space. It helps to early-stage start-ups within human health and planetary health. The startup'smission is to use its knowledge, network, funding, and infrastructure to incubate world-class life science and catalyze the commercialization of new solutions through start-ups.BioInnovation Institute was founded in 2018 and is based in Denmark.
Show more...Investment focus
- Industry: Biotechnology, Medical, Health Care
- Stage:Convertible Note, Pre-Seed, Seed
- Geography: Denmark, Germany, Switzerland
Investor stats
- Total investments: 93
- Round size: Seed $532k–$1.8M; Pre-Seed $530k–$5.2M; Convertible Note $495k–$1.6M
- Lead/follow: 92% lead, 8% follow
Portfolio highlights
- Visibuilt — Visibuilt develops sustainable, bio-based asphalt binders made from mycelium. Replace fossil bitumen with visiBIT.
- Agrobiomics — Agrobiomics is a danish Agritech start-up, harnessing the power of soil bacteria and their metabolites as new biostimulants to help crops cope with abiotic stress such as drought.
- metaLead Therapeutics — metaLead Therapeutics is to develop this peptide as a next-generation Pb poisoning treatment.
Vaekstfonden – The Danish Growth Fund – is the Danish state's investment fund. We strive to improve access to risk capital to enable Danish businesses to innovate, and to generate growth and new jobs. In close collaboration with banks and domestic and international private investors, we finance companies from all sectors nation-wide. We canaccompany you for the entire journey – from your company’s infancy through growth phases to expansion abroad and even to an initial public offering.
Show more...Investment focus
- Industry: Software, Information Technology, SaaS
- Stage:Seed, Venture - Series Unknown
- Geography: Denmark, United States, United Kingdom
Investor stats
- Total investments: 227
- Round size: Seed $899k–$4.9M; Venture - Series Unknown $1.2M–$23M
- Lead/follow: 28% lead, 72% follow
- Last fund: Likely still investing — raised $343M in 2023
Portfolio highlights
- Advalight — Advalight is a young, dynamic company dedicated to providing high-quality laser equipment for dermatological treatments. The company has patented an innovative technology for use in the removal of vascular lesions, acne treatment, skin rejuvenation and many other skin-enhancing procedures. The ground-breaking product was launched the summer 2014.Advalight is based on five years of scientific work in the Physics Department at the Technical University of Denmark. The founders include two PhDs and it is their research that forms the basis of Advalight. The company's main focus is on research and development and with the right external partners we believe that the market for dermatological lasers will be transformed. Advalight is therefore seeking collaboration with external partners with established distribution and sales channels.
- BluePrinter — Today, 3D prints are usually either outsourced or centrally produced within corporations, needlessly costing valuable time and money. With Blueprinter, the 3D printing process is possible to insource within departments, and has become affordable for small businesses. Blueprinter decentralizes the 3D printing by moving the printer from thecentral laboratory, or external service providers, to within the office – decreasing the time to market, saving significant money in prototyping, and keeping confidentiality for all original prototypes.
- DITA Exchange — DitaExchange is a CCMS built on Microsoft SharePoint, authored in Word. For organizations where content accuracy has consequences.
Denmark's Export and Investment Fund (EIFO) serves as a single point of contact for Danish firms seeking risk-tolerant government finance. We aspire to help successful enterprises that can expand the Danish economy and green the world on a daily basis, guided by professionalism and an international perspective.
Show more...Investment focus
- Industry: Software, Biotechnology, Health Care
- Stage:Seed, Series A, Pre-Seed
- Geography: Denmark, United States, Norway
Investor stats
- Total investments: 146
- Round size: Seed $395k–$11M; Pre-Seed $807k–$2.9M; Series A $5.9M–$84M
- Lead/follow: 37% lead, 63% follow
Portfolio highlights
- Sovera Security — Sovera was established to develop that model, which is self-improving, signal-driven, and sovereign.
- Breye Therapeutics — Breye Therapeutics, a Danish-based biopharmaceutical firm in the clinical stages, is working to provide cutting-edge oral treatments for the management of retinal vascular diseases.
- Onomondo — Onomondo is a global IoT network. Our IoT SIM and cloud platform future proof your devices with full data transparency, freedom to leave, and no third parties.
Seed Capital invests in Danish tech businesses with global ambitions. We are focused on "late seed"-stage companies, typically investing 1-3 MEUR in rounds of 1-6 MEUR. Proud backers of Trustpilot, Vivino, Lunar, Templafy, Dixa, Forecast, and many other great companies.
Show more...Investment focus
- Industry: Software, Health Care, Information Technology
- Stage:Seed, Venture - Series Unknown
- Geography: Denmark, United States, United Kingdom
Investor stats
- Total investments: 201
- Round size: Seed $508k–$5.5M; Venture - Series Unknown $513k–$5.1M
- Lead/follow: 31% lead, 69% follow
- Last fund: May invest from a new fund soon — raised $74M in 2021
Portfolio highlights
- Tailify — Influencer Marketing, Powered by Behavioural Science. We're Tailify, the influencer marketing agency that combines the power of influence with the science of human behaviour.
- Reapplix — Reapplix ApS, a research and development company, identifies blood-derived proteins that improve wound healing, isolates them, and reapplies them to patients with chronic wounds. The company was founded in 2008 and is based in Birkerod, Denmark.
- Neurescue — Neurescue, a medical device manufacturer based in Denmark, is developing cardiovascular devices to help emergency patients. Neurescue’s first product, the safeREBOA device, is the first computer-aided aortic occlusion catheter. Our future goal is to enable the potential clinical utility of further intelligent procedures.
Sunstone Life Science Ventures is an independent European venture capital investment firm. We enable and empower life science therapeutics innovations.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B
- Geography: Denmark, Sweden, Switzerland
Investor stats
- Total investments: 63
- Round size: Series A $5.5M–$61M; Series B $9.5M–$58M
- Lead/follow: 16% lead, 84% follow
- Last fund: May invest from a new fund soon — raised $92M in 2019
Portfolio highlights
- Kynexis — Kynexis is leading the way in precision medicine, focusing on the treatment of cognitive impairment associated with schizophrenia (CIAS). Explore our innovative approach and our dedication to improving the lives of millions globally.
- Step Pharma — Step Pharma is a spin-off of Imagine Institute stemming from Pr. Alain Fischer’s research on genetic immunodeficiencies. Step Pharma is a joint venture between Imagine, a research and innovative healthcare institute, Sygnature Discovery, a leading provider of integrated drug discovery resource and expertise, and Kurma Partners, a major player inthe funding of healthcare and biotechnology in Europe.
- TargED Biopharmaceuticals — TargED Biopharmaceuticals is a biotechnology company that develops first-in-class biological drugs to improve treatment of thrombosis.TargED stands for Targeted Enzyme Delivery. Their biological drugs are unique by using small antibodies (“VhH”) to deliver enzymes to sites of thrombosis, enabling ‘targeted’ thrombolysis.
PSV cares about a conscious future. As a venture house, our mission is to clear the path for founders who build companies that matter. Our hybrid setup, comprising PSV Foundry, PSV Lab, and two unique venture funds, PSV Tech and PSV Hafnium, sets us free from adhering to a singular method. Rather we rethink existing ways and models to maximise our impact beyond any individual firm or investment. Together, we can punch above our weight.
Show more...Investment focus
- Industry: Software, Information Technology, Artificial Intelligence
- Stage:Seed, Pre-Seed, Venture - Series Unknown
- Geography: Denmark, United States, Sweden
Investor stats
- Total investments: 154
- Round size: Seed $500k–$4.6M; Pre-Seed $307k–$2.5M; Venture - Series Unknown $513k–$3.2M
- Lead/follow: 36% lead, 64% follow
- Last fund: May invest from a new fund soon — raised $64M in 2020
Portfolio highlights
- Thiax — ThiaX maps the strain and crystallinity in polymer and composite materials using cutting-edge X-ray diffraction (XRD) technology.
- spektr — Automate KYB, KYC onboarding, risk monitoring, and case management, reducing false positives and manual work for faster, more secure processes.
- Acodyne — Heavy-lift eVTOL cargo UAVs. Heavy payloads, high speed, autonomous flight.
We are investing in #FutureFood. Nordic FoodTech VC is the first fund in the Nordics investing explicitly in the future of food
Show more...Investment focus
- Industry: Biotechnology, Food and Beverage, Life Science
- Stage:Seed, Pre-Seed, Series A
- Geography: Finland, Denmark, Sweden
Investor stats
- Total investments: 31
- Round size: Seed $610k–$5.3M; Pre-Seed $880k–$1.9M; Series A $6.8M–$18M
- Lead/follow: 58% lead, 42% follow
- Last fund: Likely actively investing — fresh fund, raised $42M in 2024
Portfolio highlights
- Fiberdom — Fiberdom develops sustainable materials from wood fibers, focusing on plastic-free solutions. The company offers a range of compostable cutlery designed for food service and take-away applications. These products are fully recyclable and comply with European regulations, making them suitable for environmentally conscious consumers. Fiberdomemphasizes innovation in transforming wood fibers into high-performance materials, contributing to sustainability efforts in various industries. The commitment to creating eco-friendly alternatives positions Fiberdom as a key player in the materials innovation sector.
- MÖ Foods — MÖ Kaurajogu is domestic, completely herbal and above all delicious. All our products are manufactured in Central Ostrobothnia, Lohtaja.
- AquaNab Solutions — AquaNab is a biotechnology startup developing precision immunotherapies for aquaculture. The company's core platform uses alpaca-derived nanoantibodies (called AquaNabs) formulated directly into fish feed. This approach allows the therapeutic molecules to cross the fish's intestinal barrier and target pathogens from the bloodstream.
Gilde Healthcare is a specialized European healthcare investor managing two business lines: a lower mid-market buy-out fund and a venture & growth capital fund. It has over €800 million ($900 million) under management and is actively looking to lead new investments in digital health, diagnostics, medical devices, therapeutics and healthcareservices. Gilde successfully builds healthcare businesses across Europe and US, investing up to €35 million in a single portfolio company.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series B, Series C, Series A
- Geography: United States, The Netherlands, Germany
Investor stats
- Total investments: 131
- Round size: Series A $9.5M–$62M; Series B $14M–$135M; Series C $21M–$80M
- Lead/follow: 38% lead, 62% follow
- Last fund: Likely actively investing — fresh fund, raised $296M in 2026
Portfolio highlights
- Big Health — Our mission is to help millions back to good mental health. Our digital therapeutics are safe and effective non-drug alternatives for mental health.
- GT Medical Technologies — GammaTile is an FDA-cleared, bioabsorbable collagen implant embedded with radiation seeds, designed for patients with operable brain tumors.
- Endovascular Engineering — Endovascular Engineering is a medical technology company focused on developing and deploying advanced clot removal solutions for the treatment of venous thromboembolism. It specializes in thrombectomy technologies designed to improve clinical outcomes and procedural efficiency in minimally invasive vascular interventions. The company’s flagshipinnovation is the Hēlo™ Thrombectomy System, a catheter-based device that uses a combination of mechanical agitation and physician-controlled aspiration to remove blood clots. Its technology emphasizes features such as a self-expanding funnel design and dual-action functionality to enhance clot engagement and navigation through complex anatomies. Endovascular Engineering primarily serves healthcare providers, including interventional cardiologists and radiologists, supporting the treatment of conditions such as pulmonary embolism and deep vein thrombosis.
Oskare Capital is a venture capital firm.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Seed, Series A, Pre-Seed
- Geography: Italy, Denmark, United Kingdom
Investor stats
- Total investments: 9
- Round size: Seed $1.2M–$3.4M; Series A $4.7M–$5.9M
- Lead/follow: 56% lead, 44% follow
Portfolio highlights
- Leva Clinic — Leva Clinic offers health care services for people with chronic pain. Their medical services include back pain, cancer pain, endometriosis, facial pain, fibromyalgia, joint pain, knee pain, multiple sclerosis, sciatica, and so on.
- Octarine Bio — Octarine Bio is a world leading synthetic biology platform with a core mission to drive bio-based, sustainable solutions to address the most pressing planetary issues through innovation & exploration. Inspired by nature, to protect nature.
- Herbolea Biotech — Unique bio-processing technologies NATURAL, SOLVENT-LESS Botanical extraction Learn more
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!RA Capital Management is an investment advisor based in Boston specializing in the life-sciences and drug development sectors. The company's team has been investing since 2002 and is comprised of professionals with training in biology, chemistry, and medicine and also has industry and business development experience at the executive and boardlevels. The company invests in companies with promising technologies and products.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series B, Post-IPO Equity, Series A
- Geography: United States, United Kingdom, China
Investor stats
- Total investments: 578
- Round size: Series A $20M–$128M; Series B $27M–$151M; Post-IPO Equity $35M–$275M
- Lead/follow: 35% lead, 65% follow
- Last fund: Likely actively investing — fresh fund, raised $120M in 2025
Portfolio highlights
- Serapha Bio —
- Windward Bio — Windward Bio is a clinical-stage, drug development company committed to improving outcomes for people living with serious immunological diseases.
- Lisata Therapeutics — Lisata is a clinical-stage pharmaceutical company dedicated to improving lives through the discovery, development, and commercialization of innovative medicines.
2xN operates as a venture capital firm.
Show more...Investment focus
- Industry: Software, Information Technology, Quantum Computing
- Stage:Seed, Series A, Series B
- Geography: Denmark, United States, United Kingdom
Investor stats
- Total investments: 36
- Round size: Seed $1.9M–$6.9M; Series A $6.4M–$63M; Series B $15M–$125M
- Lead/follow: 11% lead, 89% follow
- Last fund: Likely still investing — raised $120M in 2022
Portfolio highlights
- Kvantify — Quantum computing will revolutionize many aspects of computing. We can help your business harness the full potential of Quantum Computing and High-Performance Computing today.
- QSimulate — QSimulate is a simulation platform that solves pressing problems for the chemical and pharmaceutical industries. It aims to deliver best-time-to-solution algorithms to chemical and pharmaceutical industries to accelerate their computational R&D. It is headquartered in Cambridge, Massachusetts.
- Sparrow Quantum — Sparrow Quantum, a global leader in quantum photonic chip technology. Explore innovative solutions driving advancements in quantum computing, communication, and beyond. Stay ahead with cutting-edge technologies shaping the future.
West Hill Corporate Finance is a leading private equity venture capital firm providing EIS qualifying high-growth investments to private individuals.
Show more...Investment focus
- Industry: Health Care, Information Technology, Software
- Stage:Venture - Series Unknown, Series A, Seed
- Geography: United Kingdom, Denmark, Germany
Investor stats
- Total investments: 61
- Round size: Seed $2.6M–$6M; Series A $2M–$15M; Venture - Series Unknown $1.8M–$10M
- Lead/follow: 82% lead, 18% follow
Portfolio highlights
- Silicon MicroGravity — Silicon Microgravity Limited is a spin-out from Cambridge University. The underpinning sensor technology was developed through a collaboration with BP plc and provides a breakthrough in the management of oil and gas reservoirs. The technology has been developed in Cambridge University’s Nanoscience Centre primarily funded by BP and Innovate UK.
- ATLANT 3D — Micro and nanodevices are built and tested within days instead of months or years.
- Formalize — Formalize delivers a cloud-based compliance operations platform designed for governance, risk, and control workflows, enabling businesses to automate processes around frameworks such as NIS2, DORA, ISO 27001, and GDPR. The platform lets users centralize risk and incident tracking, manage third-party audits and controls, and build customizeddashboards and workflows across compliance, supplier management, and governance.
Innovators in nutrition, health, and beauty. Together, we bring progress to life by combining the essential, the desirable, and the sustainable.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Manufacturing
- Stage:Series A, Series B
- Geography: United States, Canada, Israel
Investor stats
- Total investments: 96
- Round size: Series A $3.5M–$32M; Series B $5.6M–$30M
- Lead/follow: 51% lead, 49% follow
- Last fund: May invest from a new fund soon — last raise in 2012
Portfolio highlights
- Athian — Funding livestock sustainability via a connected carbon marketplace.
- Octarine Bio — Octarine Bio is a world leading synthetic biology platform with a core mission to drive bio-based, sustainable solutions to address the most pressing planetary issues through innovation & exploration. Inspired by nature, to protect nature.
- Meala Foodtech — Revolutionary texturized plant proteins that replace eggs and hydrocolloids. Clean-label, allergen-free solutions for baking, savory foods, and dressings.
PINC was launched as Paulig Incubator in 2018 to help Paulig stay in the forefront of relevant innovations, as well as to contribute to a tastier, healthier and more sustainable planet. Today, our ambition is the same, but we have developed into a corporate venture arm. We aim for strategic, financial, and societal impact in our investments,fostering a sustainable food system for tomorrow. We are investing across the agrifood value chain in three primary impact themes: Improve planetary health and diet within the current food system: This includes innovations in agriculture and food security, such as advanced crop breeding or green fertilizers, innovative ingredients and next generation healthy foods, as well as solutions for tracking and improving climate and nature. Novel technologies to feed 10 BN people by 2050: Technologies needed to sustainably produce enough food for our growing population. This includes food production without land use change, such as precision fermentation and cell-culture. A circular system for food & materials: Regardless of whether we grow our food in soil or in bioreactors, the system needs to be circular. Some examples are upcycled ingredients, food from unused sources, new coating and packaging solutions, as well as technologies to prevent or make better use of side streams. We are looking for entrepreneurs in an attractive market space with an intrinsic drive to find a solution to the problem they are addressing, a clear and scalable plan for success, a reliable team and partners whom we can trust and work closely with.
Show more...Investment focus
- Industry: Biotechnology, Food and Beverage, Agriculture
- Stage:Seed, Pre-Seed, Series A
- Geography: Sweden, Denmark, United Kingdom
Investor stats
- Total investments: 23
- Round size: Seed $907k–$7M; Pre-Seed $89k–$2.8M; Series A $4.1M–$7.2M
- Lead/follow: 26% lead, 74% follow
Portfolio highlights
- Amatera — Amatera is a biotechnology research company that leverages the latest techniques in biotechnology, to create coffee varieties. Amatera urges to make coffee varieties more sustainable and climate resistant to fill that massive demand. Founded by Omar Dekkiche and Lucie Kriegshauser in 2022 and is located in Paris, France.
- Mycoverse — Mycoverse is a agri-biotech startup specializes in developing fungal-based biological crop protection solutions to replace chemical pesticides, targeting row crops with an initial focus on potato late blight.
- Rainbow Crops — Rainbow Crops is a next-generation Agtech company developing climate-resilient, high-performing crop varieties.
Vaekstfonden makes equity investments in Danish companies with a track record as well as in young entrepreneurial, innovative enterprises with an ambition for global growth.
Show more...Investment focus
- Industry: Software, Biotechnology, Medical Device
- Stage:Seed, Series A, Venture - Series Unknown
- Geography: Denmark, United Kingdom, Iceland
Investor stats
- Total investments: 32
- Round size: Seed $1.2M–$9.1M; Series A $1.5M–$23M; Venture - Series Unknown $2.8M–$31M
- Lead/follow: 28% lead, 72% follow
Portfolio highlights
- Rokoko — Rokoko | Affordable high-end motion capture and animation tools for body, hand, and face capture + software with native integrations for all major animation software and game engines
- Kollektiv — Unleash your best self with tailored training plans, learning and support for running, swimming and cycling - from world-class-coaches and ex-athletes.
- Performativ — Performativ develops modern solutions for the asset and wealth management industry. Our clients span from small investment advisors to enterprise banks.
EIR Ventures is a new Life Science Venture Group in the Nordics.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Seed
- Geography: Denmark, Sweden, United States
Investor stats
- Total investments: 13
- Round size: Series A $20M–$73M
- Lead/follow: 54% lead, 46% follow
- Last fund: Likely still investing — raised $138M in 2021
Portfolio highlights
- ArgusEye — ArgusEye is a biotechnology company that provides sensor solutions for real-time detection of biological systems and processes. ArgusEye's patented sensor technology is the result of extensive academic research and is based on nanoplasmonic sensing with fiber optics. By adding customized receptors, ArgusEye can offer flexible and sensitivesensing systems for a variety of targets.
- Moleculent — Moleculent is adding a functional layer of biology to pave the way for unparalleled advancements in biological research.
- Hoba Therapeutics — Hoba Therapeutics is developing a new therapeutic protein for the treatment of neuropathic pain.
Leading #lifesciences #venturecapital firm financing highly #innovative #biotechnology companies #worlwide.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: Spain, United States, Switzerland
Investor stats
- Total investments: 86
- Round size: Series A $3.8M–$65M; Series B $17M–$135M; Series C $29M–$83M
- Lead/follow: 28% lead, 72% follow
- Last fund: May invest from a new fund soon — raised $246M in 2020
Portfolio highlights
- AM Pharma — AM-Pharma B.V., a biopharmaceutical company, engages in the development and commercialization of therapeutics for human use in the Netherlands. It focuses in the pre-clinical and clinical development of novel therapeutics to treat inflammatory and infectious diseases. The company develops products based on endogenous proteins and protein derivedpeptides, as well as molecules that naturally occur in the human body. Its products include alkaline phosphatase for treatment of acute kidney injury and ulcerative colitis; and immune response amplifying peptide hLF1-11 for the treatment of drug resistant hospital acquired infections. The company was founded in 2000 and is headquartered in Bunnik, the Netherlands.
- Inbiomotion — Inbiomotion is focused on the development and commercialization of a biomarker that predicts metastasis to improve patients' quality of life by personalizing the adjuvant treatment of early stage breast cancer. Founded in 2010 by Dr. Roger Gomis, it is a spin-off of IRB Barcelona and ICREA research institutions.Inbiomotion's uniquediagnostic assay is based on a highly selective single gene biomarker. Data generated thus far suggests such biomarker can identify early stage breast cancer patients that will benefit from bisphosphonate adjuvant treatment improving their overall and invasive disease free survival. It can further predict at an early stage a patient's risk of metastases relapse from primary tumors. The selectivity of the lead biomarker has the potential to advance the clinical standard of care using personalized medicine.
- Anaconda BioMed — Anaconda Biomed, headquartered in Barcelona, Spain, is among the world's most innovative early stage medical technology companies. The company was founded by Dr. Ofir Arad and Dr. Marc Ribó in 2015, and is developing the ANCD BRAIN™, a novel 3rd Generation Stented Aspiration Thrombectomy System for the treatment of Acute Ischemic Stroke (AIS).
ACME Capital is a venture capital and private equity firm that invests in breakthrough technologies that fuel platform shifts and disruptive business models that capitalize on new platforms. Its purpose is to support those founders who choose to take their capital. The firm was founded in 2018 and headquartered in San Francisco, California.
Show more...Investment focus
- Industry: Software, Health Care, Artificial Intelligence
- Stage:Seed, Series A, Series B
- Geography: United States, Denmark, Canada
Investor stats
- Total investments: 197
- Round size: Seed $1.6M–$10M; Series A $4.4M–$28M; Series B $15M–$65M
- Lead/follow: 23% lead, 77% follow
- Last fund: Likely still investing — raised $10M in 2022
Portfolio highlights
- Treon — Treon is a product company in the business of offering intelligent IOT products and solutions and custom design services for connected devices. Their customer base is global and in multiple industry verticals. They specialize in highly integrated industrial design led products utilising mobile industry technologies where their founders have a verystrong backround in new mobile innovations.
- Stendr — AI-powered air defense consolidating sensors into real-time operational view. Built for modern drone threats. NATO-aligned European sovereignty.
- Plot — We power the best creative teams to help streamline creative development and cross-collaborate in one source of truth.
A passion and vision for chemistry and biotechnology led Per (born 1958) to Novo A/S, where he started his career as a research chemist. He subsequently held several managerial positions developing products for the detergent industry and rose to Director for Application Technology in the company’s new enzyme development division in 1995.Hemoved to Raleigh, N.C., to head the company’s U.S. application technology unit in 1997, returning to Denmark three years later as Corporate Vice President of the Enzyme Development and Application division. In April 2000, Per merged the Research and Development division into the newly formed Enzyme Business R&D.Per assumed his current position following Novozymes’ demerger from Novo Nordisk in 2000. As chief science officer, he has helped Novozymes develop a unique industrial biotechnology platform which delivers solutions to meet customer needs and support growth.Per holds a M.Sc. in Chemical Engineering from Technical University of Denmark (DTU). Committed to promoting education and research within the sciences, he was appointed Honorary Professor at DTU’s Institute for Systems Biology in 2010 and became Chairman of the Board in 2013. He is also Chairman of the Young Scientists association in Denmark.Per’s current external positions also include Chairman, DTU, board member of DHI Group, board member of ARTs Biologics A/S, and member of the Danish Council for Research Policy.
Show more...Investment focus
- Industry: Biotechnology, Robotics, Biopharma
- Stage:Pre-Seed, Series A, Seed
- Geography: Denmark
Investor stats
- Total investments: 5
- Round size: Series A $5.9M–$20M
- Lead/follow: 20% lead, 80% follow
Portfolio highlights
- Visibuilt — Visibuilt develops sustainable, bio-based asphalt binders made from mycelium. Replace fossil bitumen with visiBIT.
- Octarine Bio — Octarine Bio is a world leading synthetic biology platform with a core mission to drive bio-based, sustainable solutions to address the most pressing planetary issues through innovation & exploration. Inspired by nature, to protect nature.
- Synamics Therapeutics — Synamics Therapeutics uses AI and predictive modeling for precision oncology and improved drug discovery. Our adaptive medicine approach helps prolong drug effectiveness and improves outcomes for patients with intractable cancers. Learn more about Synamics Therapeutics and how we leverage AI for personalized, adaptive cancer therapies.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Atlantic Labs supports and invests in mission-driven founders working on transformative technology ventures. <br><br>We partner with founders early, providing the capital, tools and network necessary to growing their companies and accompanying them on their entrepreneurial journey. We are currently active in areas including Digital Health, Future of Work, Machine Learning, Decentralized Networks, Mobility and Industrial Applications.
Show more...Investment focus
- Industry: Software, Health Care, Artificial Intelligence
- Stage:Seed, Series A, Pre-Seed
- Geography: Germany, Switzerland, United States
Investor stats
- Total investments: 272
- Round size: Seed $1.1M–$9.4M; Pre-Seed $850k–$3.5M; Series A $4.5M–$30M
- Lead/follow: 47% lead, 53% follow
- Last fund: Likely still investing — raised $110M in 2022
Portfolio highlights
- 42matters — 42matters offers a full suite of mobile and connected TV app intelligence solutions, including APIs, file dumps, and visual, web-based platforms.
- Phase0 — Payment platform for construction projects
- Lightspring — Lightspring is a photonics technology company developing advanced 3D optical interconnection solutions for photonic systems.
HealthCap, a life science investor and company creator. Our motivation is to find innovative ideas and invest that could impact healthcare and society.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series B, Series A
- Geography: United States, Sweden, France
Investor stats
- Total investments: 141
- Round size: Series A $6M–$73M; Series B $12M–$92M
- Lead/follow: 26% lead, 74% follow
- Last fund: Likely still investing — raised $179M in 2024
Portfolio highlights
- Neobiomics — Neobiomics is a Swedish life-science company that develops nutritional products for preterm infants and neonatal care. Its best-known products include ProPrems® and NeoMega36®.
- AMRA Medical — AMRA Medical is a digital health company transforming medical research and clinical care using rapid whole-body MRI technology.
- Ultragenyx Pharmaceutical — Ultragenyx is focused on developing first-ever approved treatments for rare and ultrarare diseases and moving the rare disease community forward.
Karolinska Development aims to create value for patients, researchers, investors and society by developing innovations from world class science into products that can be sold or out-licensed with high returns. The business model is to: SELECT the most commercially attractive medical innovations; DEVELOP innovations to the stage where the greatestreturn on investment can be achieved; and COMMERCIALIZE the innovations through the sale of companies or out-licensing of products.Karolinska Development has developed a well-structured selection process to identify the most commercially attractive medical innovations screened by KIAB. Pharmaceutical development is a high-risk enterprise. In most cases, development projects fail because of side effects or insufficient efficacy. Successful selection of innovations is fundamental to Karolinska Development’s business model, which makes the inflow of new projects crucial. One key to success lies in selecting those innovations that can be developed from scientific findings to products and have significant commercial potential. To date, over 1,300 projects have been screened by KIAB.The portfolio companies are often founded together with the innovators and are initially operated as virtual companies with few or no employees. During the first six to twelve months, the companies normally have minimal fixed costs and technological development is outsourced.The innovator, who is often employed at an academic institution, normally participates as a board member and scientific advisor. The CEO of a portfolio company cooperates closely with a representative of Karolinska Development, who in most cases is also a board member of the company. The companies are capitalized to reach their next milestone, usually within a period of six to eighteen months. Development projects are continuously monitored, and those that do not meet their stipulated targets are discontinued. In the first three to four years, a portfolio company’s operating expenses are often limited to a few million Swedish kronor per year, which cover the cost of external studies and the salary of the staff. In subsequent years, Karolinska Development and other investors play an important role recruiting key expertise to the companiesKarolinska Development intends to realize value by exiting portfolio companies or through out-licensing of projects. Such transactions (especially out-licensing) are often structured as single upfront payments followed by payments based on predetermined milestones and royalties on sales. Although Karolinska Development has a flexible exit strategy, pharmaceutical products are, for two reasons, preferably exited at Phase II. First a successful Phase II study indicates that the pharmaceutical has an effect on patients, which is an important value-enhancing factor when negotiating out-licensing or sales. Secondly, finalizing product development and undertaking Phase III clinical trials frequently requires very large patient populations. In many cases this requires much greater resources than those available at Karolinska Development but these can be found in established pharmaceutical companies. Several licensing deals were closed in 2011 involving projects with a similar focus and development phase to Karolinska Development's projects.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Pharmaceutical
- Stage:Venture - Series Unknown, Seed
- Geography: Sweden, Denmark, United States
Investor stats
- Total investments: 32
- Round size: Venture - Series Unknown $3.2M–$10M
- Lead/follow: 34% lead, 66% follow
Portfolio highlights
- BOOST Pharma — BOOST Pharma is developing BT-101, an off-the-shelf therapy for early intervention in children with severe osteogenesis imperfecta (OI).
- Modus Therapeutics — Modus Therapeutics is a Swedish drug development company developing sevuparin – a novel drug to treat people suffering from Sickle Cell Disease – a painful, inherited blood disorder affecting millions of people around the globe.
- Umecrine Cognition — Umecrine Cognition is a Swedish clinical-stage pharmaceutical company developing a novel class of drugs to treat neurological disorders of the brain.
Nicholas Francis is based out of Copenhagen, Hovedstaden, and is the Founder of Francis Family Funds. Nicholas previously worked at framebunker as a Co-Founder.
Show more...Investment focus
- Industry: SaaS, Robotics, Software
- Stage:Seed, Series A
- Geography: Denmark, United States
Investor stats
- Total investments: 4
- Round size: Seed $983k–$8.1M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Waterplan — Waterplan creates a water resilience planning platform for managing water availability in facilities. The company employs artificial intelligence to automatically collect operational data from businesses and combine it with local water satellite imagery to provide a real-time financial assessment of water risk and to offer modified mitigation andadaptation options.
- Reshape Biotech — Fully digital microbiology developed by Reshape Biotech
Innovation Fund Denmark invests in the development of new knowledge and technology creating growth and employment in Denmark. The Fund focuses on societal challenges, strengthens research, and increases innovation commitment within private companies.The Fund provides risk capital that enables cutting-edge initiatives to achieve resultssubstantially impacting the Danish society. Innovation Fund Denmark is also responsible for the future societal partnerships, where companies, universities, and public authorities will work together on challenges facing the society today.
Show more...Investment focus
- Industry: Software, Biotechnology, SaaS
- Stage:Grant, Pre-Seed, Seed
- Geography: Denmark, United States
Investor stats
- Total investments: 97
- Round size: Seed $66k–$2.1M; Grant $35k–$1.1M; Pre-Seed $64k–$1.6M
- Lead/follow: 33% lead, 67% follow
Portfolio highlights
- Prezio — Access comprehensive electricity tariff data across Europe via one API
- PerPlant — PerPlant gives tractors the ability to see every plant. AI-powered cameras that cut input costs by 50% on average.
- SureShot — SureShot empowers you and your audience to become video co-creators. With our cutting-edge AI, capture, edit, and share electrifying videos that amplify the essence of every event.
Blue Horizon is accelerating the transition to a sustainable food system that delivers outstanding returns for the planet and people.
Show more...Investment focus
- Industry: Food and Beverage, Food Processing, Biotechnology
- Stage:Seed, Series A, Pre-Seed
- Geography: United States, United Kingdom, Germany
Investor stats
- Total investments: 109
- Round size: Seed $2M–$10M; Pre-Seed $450k–$6.3M; Series A $2M–$40M
- Lead/follow: 28% lead, 72% follow
- Last fund: May invest from a new fund soon — raised $222M in 2021
Portfolio highlights
- WOW EARN — Discover WOW EARN, the all-in-one Web3 app with crypto mining, multi-chain wallet, staking NFTs, and marketplace dApps. Join the global Web3 community today.
- EV Biotech — DANU strain engineering creates Precision Biopolymers For High-Performance Applications through strain engineering and AI.
- foodforecast — AI supported solution to reduce food waste.
WE ARE AN EARLY-STAGE INVESTOR IN ONE OF THE MOST DYNAMIC AND ESSENTIAL FIELDS OF CURRENT HUMAN ENDEAVOR WE BRING ROBUST INVESTOR MUSCLE TO EARLY-STAGE VENTURES INVESTOR A specialized and focused investor Resources Powerful industry, substance and business resources Experience Wide networks and longstanding experience Team Yet, adaptability and speed of a lean, self-financed team
Show more...Investment focus
- Industry: Biotechnology, Health Care, Manufacturing
- Stage:Series A, Seed, Pre-Seed
- Geography: United States, France, Denmark
Investor stats
- Total investments: 22
- Round size: Seed $3.4M–$20M; Series A $6.8M–$48M
- Lead/follow: 14% lead, 86% follow
Portfolio highlights
- EvodiaBio — EvodiaBio is a bio-industrial firm that creates natural, sustainable scents for the food and beverage industries. Founded in 2021 and is based in Copenhagen, Capital Region.
- uFraction8 — Multi-award-winning, innovative, microfluidics-based filter systems to provide bio-manufacturers with energy-efficient & ultra-scalable bioprocessing systems.
- Switch Bioworks — Switch Bioworks engineers symbiotic microbes to produce sustainable nitrogen fertilizer under the control of precise genetic circuits.
Noon Ventures is a Copenhagen-based, early-stage venture investor established in 2020. We invest in proven transformative technologies with the potential to impact environmental or climate challenges.
Show more...Investment focus
- Industry: Biotechnology, AgTech, Farming
- Stage:Seed, Series A
- Geography: Denmark
Investor stats
- Total investments: 6
- Round size: Seed $4.3M–$8.8M
- Lead/follow: 83% lead, 17% follow
Portfolio highlights
- Agrobiomics — Agrobiomics is a danish Agritech start-up, harnessing the power of soil bacteria and their metabolites as new biostimulants to help crops cope with abiotic stress such as drought.
- Enduro Genetics — Bioproduction can be difficult to scale to large cultivation volumes while keeping titers high. By applying game-changing synthetic biology technology, Enduro Genetics empowers our partner companies to maximize performance of all cells cultivated from their production strains.
- Lotus Microsystems — Lotus Microsystems offers miniaturized highly integrated point of load power converters. The devices are engineered for portable electronics manufacturers ready for usage whenever tiny power supply units are needed. Our devices offer up to 72% reduction in footprint compared to existing solutions with higher efficiency and reliability. Our plug andplay solutions enable our customers to innovate their electronics without worrying about power supply units.
High-Tech Grunderfonds finances startups with growth potential. Its team of investment managers supports young companies with expertise, entrepreneurial spirit, and passion. The company focuses in the fields of digital tech, industrial tech, life sciences, chemistry, and related business areas. It also focuses on financial services in varioussectors.
Show more...Investment focus
- Industry: Software, Biotechnology, Information Technology
- Stage:Seed, Series A, Pre-Seed
- Geography: Germany, Switzerland, United States
Investor stats
- Total investments: 771
- Round size: Seed $790k–$6.9M; Pre-Seed $841k–$2.8M; Series A $3M–$31M
- Lead/follow: 35% lead, 65% follow
- Last fund: Likely still investing — raised $515M in 2022
Portfolio highlights
- Extoll — EXTOLL, a leader in high-speed, ultra-low power SerDes and Chiplet connectivity, offers semiconductor IP with the smallest footprints and highest PPA. Serving global ASIC, SoC, and Chiplet markets, our portfolio includes tailored NoC (Network-on-Chip) and Die-to-Die solutions. EXTOLL drives innovation, enabling successful migration into the Chiplet Age.
- BlueID GmbH — Smart locks for professionals. BlueID delivers flexible, secure and convenient smart locks for all doors in and around your office.
- CenterPoint - Connective Software Engineering — CenterPoint was founded in 2000 and is based in Villach, Austria with an additional office in Warsaw, Poland. CenterPoint - Connective Software Engineering develops and markets process control and fault detection and classification software solutions. The company offers cause effect analysis, metrology assessment, and close loop and run to runcontrol services. It's focus are the semiconductors, electronics, and steel and alloy industries.
We aim to invest in exceptional founders and entrepreneurs and impactful products and platforms across multiple therapeutic areas.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Series C
- Geography: United States, Switzerland, United Kingdom
Investor stats
- Total investments: 172
- Round size: Series A $16M–$200M; Series B $38M–$165M; Series C $14M–$208M
- Lead/follow: 28% lead, 72% follow
- Last fund: Likely still investing — raised $470M in 2023
Portfolio highlights
- Ousia Pharma — Ousia Pharma is paving the way for novel therapeutic strategies using peptide-drug-conjugates
- Windward Bio — Windward Bio is a clinical-stage, drug development company committed to improving outcomes for people living with serious immunological diseases.
- Anaconda BioMed — Anaconda Biomed, headquartered in Barcelona, Spain, is among the world's most innovative early stage medical technology companies. The company was founded by Dr. Ofir Arad and Dr. Marc Ribó in 2015, and is developing the ANCD BRAIN™, a novel 3rd Generation Stented Aspiration Thrombectomy System for the treatment of Acute Ischemic Stroke (AIS).
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Bioqube Ventures helps science succeed by turning discoveries into transformative medicines.
Show more...Investment focus
- Industry: Biotechnology, Therapeutics, Life Science
- Stage:Seed, Series A, Series B
- Geography: United States, France, Norway
Investor stats
- Total investments: 18
- Round size: Seed $5.7M–$24M; Series A $4M–$76M; Series B $23M–$108M
- Lead/follow: 33% lead, 67% follow
- Last fund: May invest from a new fund soon — last raise in 2020
Portfolio highlights
- Actithera — Actithera is a molecular radiotherapeutic company that develops radioligand therapies. It translates medicinal chemistry insights into new radioligand therapies (RLTs) and applies various molecular design strategies, including covalent targeting and an isotope-agnostic philosophy, to invent RLTs with significant differentiation and largertherapeutic windows.
- Spica Therapeutics — Spica Therapeutics is a biotech company to transform macrophage biology into breakthrough therapies for patients.
- Primmune Therapeutics — Primmune Therapeutics is developing small molecule, orally-administered toll-like receptor 7 (TLR7) agonists to attack tumors and potentiate adaptive cancer immunotherapies, such as checkpoint inhibitors, to improve overall response rates and treatment durability.
Dawn Biopharma is a global investment firm of KKR.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Seed, Series B
- Geography: United States, Denmark, France
Investor stats
- Total investments: 14
- Round size: Seed $15M–$32M; Series A $17M–$165M; Series B $115M–$135M
- Lead/follow: 21% lead, 79% follow
Portfolio highlights
- ADCendo — ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment.
- Vedana Therapeutics — Vedana Therapeutics is a Seattle biotechnology company developing next-generation antibody therapies for migraine prevention.
- Expedition Therapeutics — Redefining Care. Advancing COPD and Other Respiratory Therapies. Expedition Therapeutics is developing novel treatments for inflammatory and respiratory diseases with the potential to fundamentally transform patient care worldwide. ABOUT US At Expedition Therapeutics, we believe that disease-controlling treatments that address fundamental disease mechanisms should be the new standard for chronic obstructive pulmonary disease (COPD). Our
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: France, United States, United Kingdom
Investor stats
- Total investments: 353
- Round size: Series A $7M–$70M; Series B $10M–$105M; Series C $12M–$100M
- Lead/follow: 47% lead, 53% follow
- Last fund: Likely actively investing — fresh fund, raised $755M in 2025
Portfolio highlights
- Odoo — From ERP to CRM, eCommerce and CMS. Download Odoo or use it in the cloud. Grow Your Business.
- HighLife — HighLife is driven by a mission to deliver innovative treatment options to patients suffering from heart valve diseases.
- EnginZyme — Enzymatic chemistry for cleaner ingredients in personal care, food and pharma. Enginzyme's patented EziG platform makes enzymes work at industrial scale.
At Ugly Duckling Ventures, we make capital, know-how, and real-world application available to Nordic ventures at the seed & pre-seed stage. We are operational by nature and want to get in the grind as we excel at getting early-stage ventures ready for scale.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Information Technology
- Stage:Seed, Pre-Seed, Venture - Series Unknown
- Geography: Denmark, Sweden, Finland
Investor stats
- Total investments: 25
- Round size: Seed $1M–$5.5M; Pre-Seed $917k–$1.7M; Venture - Series Unknown $1.1M–$7.5M
- Lead/follow: 60% lead, 40% follow
- Last fund: Likely actively investing — fund raised in 2026
Portfolio highlights
- Velatir — Velatir helps you stay in control of AI decisions. With real-time monitoring, AI risk scoring, we make responsible, transparent AI easy.
- Wilmo AI — AI agents that resolve ecommerce support tickets on autopilot. Automate order tracking, returns, and customer service across every channel.
- Spiich Labs — AI for revenue teams that win on relationships. The agentic sales platform that eliminates CRM admin: your CRM updates itself after every call, you get daily meeting briefs, and follow-ups write themselves. Save 9+ hours weekly.
Lundbeckfond Ventures is an evergreen life science venture fund established in the autumn of 2009 and wholly owned by the Lundbeck Foundation. The structure as an evergreen fund allows flexibility in the investment approach and the possibility, when appropriate, to take a long-term perspective in the investments. On an annual basis, LundbeckfondVentures invests up to € 50 million.Lundbeckfond Ventures is a financially driven venture fund generating returns to support the group's activities and operating independently from the Lundbeck Foundation’s controlling ownerships in H. Lundbeck A/S, ALK-Abelló and Falck.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series B, Series A, Series C
- Geography: United States, Denmark, United Kingdom
Investor stats
- Total investments: 72
- Round size: Series A $10M–$50M; Series B $20M–$95M; Series C $10M–$53M
- Lead/follow: 32% lead, 68% follow
Portfolio highlights
- Kvantify — Quantum computing will revolutionize many aspects of computing. We can help your business harness the full potential of Quantum Computing and High-Performance Computing today.
- SNIPR Biome — We are the CRISPR Microbiome Company; Our mission is to develop CRISPR-based medicines that give hope for effective and safe treatment of difficult-to-treat diseases in the future.
- Women in Life Science Denmark — WiLD is a networking platform for women in senior positions in business and academia that is motivating and focused on science.
Unconventional Ventures invests in startups in the pre-seed and seed stage led by diverse founders identifying as women, people of color, immigrants and/or LGBTQ+, building scalable impact tech companies in the Nordics and beyond.
Show more...Investment focus
- Industry: Health Care, Software, Wellness
- Stage:Seed, Pre-Seed, Series A
- Geography: Sweden, Denmark, United Kingdom
Investor stats
- Total investments: 20
- Round size: Seed $1M–$5.2M; Pre-Seed $1.5M–$2.8M; Series A $4.7M–$18M
- Lead/follow: 45% lead, 55% follow
- Last fund: Likely still investing — raised $31M in 2022
Portfolio highlights
- Visibuilt — Visibuilt develops sustainable, bio-based asphalt binders made from mycelium. Replace fossil bitumen with visiBIT.
- Boldr — Sustainability meets design. Save money and live more sustainably with Boldr products.
- Digiclean Solutions — AI-powered process chemical control that gives you lower costs, higher efficiency, and a radically smaller footprint.
The Footprint Firm is an advisory and investment company with a sole focus on sustainability.
Show more...Investment focus
- Industry: Software, Renewable Energy, Energy Management
- Stage:Seed, Pre-Seed, Series A
- Geography: Denmark, Spain, Norway
Investor stats
- Total investments: 25
- Round size: Seed $2.2M–$5.4M; Pre-Seed $863k–$4M; Series A $4.7M–$18M
- Lead/follow: 28% lead, 72% follow
- Last fund: Likely still investing — raised $54M in 2024
Portfolio highlights
- Vaja — Vaja is on a mission to accelerate the transition to a net-zero world via disruptive innovations for solar farms.
- Reel Energy — Reel empowers all companies to procure renewable electricity that makes a real difference for the climate.
- Kvasir Technologies — Imagine a world without fossil fuelsThis is where we come in! We have invented a solution that makes this possible already in 2050.
Steen Riisgaard
Show more...Investment focus
- Industry: Life Science, Therapeutics, Biotechnology
- Stage:Pre-Seed
- Geography: Denmark
Investor stats
- Total investments: 2
- Lead/follow: no public data
Portfolio highlights
- Octarine Bio — Octarine Bio is a world leading synthetic biology platform with a core mission to drive bio-based, sustainable solutions to address the most pressing planetary issues through innovation & exploration. Inspired by nature, to protect nature.
- Synamics Therapeutics — Synamics Therapeutics uses AI and predictive modeling for precision oncology and improved drug discovery. Our adaptive medicine approach helps prolong drug effectiveness and improves outcomes for patients with intractable cancers. Learn more about Synamics Therapeutics and how we leverage AI for personalized, adaptive cancer therapies.
Merck Ventures is the strategic, corporate venture capital arm of Merck. Its mandate is to invest in innovative technologies and products with the potential to significantly impact Merck‘s core business areas. From its headquarters in Amsterdam and offices in the US and Israel we invest globally in transformational ideas driven by greatentrepreneurs. Merck Ventures takes an active role in its portfolio companies and teams up with entrepreneurs and co-investors to translate innovation towards commercial success. Merck Ventures has a significant focus on early-stage investing and company creation including the creation of spin-offs to leverage Merck‘s science and technology base.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Seed
- Geography: United States, United Kingdom, Switzerland
Investor stats
- Total investments: 171
- Round size: Seed $2.4M–$22M; Series A $5.6M–$49M; Series B $15M–$100M
- Lead/follow: 38% lead, 62% follow
Portfolio highlights
- iOnctura — Our mission is to develop high impact, low disruption therapies that extend healthspan. We do this by disrupting the dynamic interplay at the heart of the
- Future Fertility — OUR AI-POWERED ASSESSMENTS GUIDE PERSONALIZED FERTILITY TREATMENT DECISIONS IN OVER 180 CLINICS ACROSS 32 COUNTRIES
- ApoGen Biotechnologies — ApoGen Biotechnologies, Inc. is focused on the development of new class of therapeutics targeting drivers of cancer genomic mutation.As the arsenal of available cancer therapies has grown and evolved from cytotoxic chemotherapy to targeted therapy to immunotherapy, one fact has unfortunately remained constant nearly all cancer drug therapieseventually fail due to the development of drug resistance. Mutation of cellular DNA is central to the formation of cancer, and chronic mutation of the cancer genome is a primary cause of cancer evolution and drug resistance, resulting in ineffective therapy, cancer recurrence and metastasis, and decreased overall survival.
SR One Capital Management is a leading trans-Atlantic biotech venture capital firm that partners with top entrepreneurs, scientists and investment partners to seek to build elite biotechnology companies. Our mission is to translate ground-breaking technologies into next generation medicines to benef
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Series C
- Geography: United States, United Kingdom, Canada
Investor stats
- Total investments: 192
- Round size: Series A $3.7M–$100M; Series B $15M–$114M; Series C $22M–$175M
- Lead/follow: 32% lead, 68% follow
- Last fund: Likely still investing — fund raised in 2023
Portfolio highlights
- Arch Oncology — Formerly Known as Vasculox. Tioma is an immuno-oncology company developing anti-CD47 antibodies for the treatment of solid and hematologic cancers. The company's functionally diverse antibodies represent a new class of checkpoint inhibitors that harness both the adaptive and innate immune responses.
- Aileron Therapeutics — Aileron Therapeutics - ALRN-6924 - myelopreservation
- AGTC — Beacon aids in restoring and improving the vision of patients with ophthalmic gene therapy. Find out more.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!They are an investment and development company providing capital, solid business experience and a strong network in order to turn innovative ideas into successful businesses. They cover all of Denmark from their offices in Aarhus, Roskilde, Copenhagen, Viborg and Kalundborg.
Show more...Investment focus
- Industry: Software, Information Technology, B2B
- Stage:Seed, Pre-Seed
- Geography: Denmark, United States, India
Investor stats
- Total investments: 24
- Round size: Seed $147k–$2.4M
- Lead/follow: 33% lead, 67% follow
Portfolio highlights
- Ulobby — Ulobby is an automated tool for stakeholder management and political monitoring
- Mechanic Miner — Mechanic Miner is a 2D construction/survival game with mechanical steam-powered machines. You are stranded on a strange and forbidding planet, where survival is made difficult by hostile animals and plant life. From your home world you did bring a multitool, which is able to craft any kind of machine part - provided the requisite rawmaterials can be found. Relying solely on the technology you brought, you set out to explore a whole world. You can progress through the game by acquiring new types of steam-powered technology elements, that are necessary to delve deeper into the diverse biomes of the planet, and perhaps, ultimately, discover the means to escape. You can construct any kind of machine of your own design - and any kind of machine can be simulated by the game's physics engine - and of course, designs can be shared with your friends.
- ResoTher Pharma — ResoTher Pharma is a privately held biotechnology company located in Copenhagen, Denmark. The company is focused on developing peptide-based drugs derived from the endogenous immunomodulator Annexin 1A as resolution therapy for diseases where neutrophil-driven inflammation plays a key pathological role.
Northzone is a multi-stage venture capital firm operating across Europe and the US. Since 1996, it has backed more than 250 companies, including Spotify, Klarna, Spring Health, and Black Forest Labs.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, FinTech
- Stage:Series A, Series B, Seed
- Geography: United States, Sweden, United Kingdom
Investor stats
- Total investments: 368
- Round size: Seed $2.5M–$23M; Series A $4.5M–$30M; Series B $7.4M–$100M
- Lead/follow: 43% lead, 57% follow
- Last fund: Likely still investing — raised $1.1B in 2022
Portfolio highlights
- Rayon — Built for Speed. Designed for Teams.
- SolveAI —
- Tandem Health — Focus on providing care, while Tandem helps you easily write medical notes directly after the patient consultation.
We deploy early stage capital to fuel the growth of need-driven health technology companies.
Show more...Investment focus
- Industry: Health Care, Artificial Intelligence, Software
- Stage:Seed, Pre-Seed, Series A
- Geography: United States, United Kingdom, Germany
Investor stats
- Total investments: 96
- Round size: Seed $2M–$6.3M; Pre-Seed $529k–$2.4M; Series A $5M–$21M
- Lead/follow: 43% lead, 57% follow
- Last fund: Likely actively investing — fresh fund, raised $52M in 2025
Portfolio highlights
- Biobase — Biobase is the agentic system for clinical data, closing the gap between clinical data and better healthcare.
- Ladder Health — Ladder Health offers virtual pediatric therapy and support for early childhood developmental delays, including speech and physical therapy.
- Woodway Assurance — Woodway Assurance provides EviData, an AI-driven software for automated privacy assurance on de-identified and synthetic datasets.
In the two decades since our founding, we have worked with hundreds of extraordinary European founders, and have raised eight funds totalling more than $3bn.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Financial Services
- Stage:Series A, Series B, Series C
- Geography: United Kingdom, United States, Germany
Investor stats
- Total investments: 465
- Round size: Series A $5M–$30M; Series B $9.3M–$100M; Series C $13M–$160M
- Lead/follow: 46% lead, 54% follow
- Last fund: Likely still investing — raised $615M in 2024
Portfolio highlights
- NewBay — NewBay enables operators and device makers to deliver a lifetime of digital content experiences across any connected device such as mobile, PC, tablets and TV. The NewBay white label software platform powers cloud-based services for storing, sharing, accessing and organizing digital content. NewBay enables customers to monetize a wide range ofbranded services such as social networking, photo and video albums, digital vault, notifications and converged messaging. NewBay is delivering highly successful commercial services for operators and device makers worldwide. Customers include T-Mobile, Telefonica O2, Orange, U.S. Cellular, AT&T, Telstra, Verizon and LG Electronics. NewBay is processing millions of messages daily and stores billions of media for live operator and device maker services. NewBay is based in Dublin, Ireland; Seattle, USA; Atlanta, USA; London, UK; Sydney, Australia and Seoul, South Korea. NewBay was founded in 2002. Following acquisition in 2011, NewBay is a wholly owned subsidiary of Research In Motion Limited (RIM).
- Socowave — Get full access to this domain. Easy, seamless transactions. Zero percent financing available.
- Spott — Spott is an AI-native ATS & CRM for Staffing and Recruiting firms.
Aescap Venture is an Amsterdam-based investment company that pursues investments in biotech companies in Europe and the U.S.
Show more...Investment focus
- Industry: Biotechnology, Pharmaceutical, Health Diagnostics
- Stage:Series B, Series A, Series C
- Geography: Switzerland, United Kingdom, The Netherlands
Investor stats
- Total investments: 20
- Round size: Series A $1.5M–$20M; Series B $5.2M–$33M
- Lead/follow: 40% lead, 60% follow
- Last fund: May invest from a new fund soon — last raise in 2016
Portfolio highlights
- Strategic Partners — Orphazyme develops innovative new therapies for the treatment of a family of serious genetic disordes called lysosomal storage diseases, and is based on discoveries emerging from the academic laboratory of its scientific founders: Professor Marja Jäättela and Thomas Kirkegaard Jensen from the Danish Cancer Society (Kræftens Bekæmpelse).Orphazyme is based in Copenhagen and has established collaborations with top-tier academic institutions in Europe and USA.
- Affectis Pharmaceuticals — Affectis is a pharmaceuticals company developing novel drugs for the treatment of neurodegenerative and neuroinflammatory diseases.
- F-Star Therapeutics — F-star is a clinical stage biotech developing next generation immunotherapies to transform the lives of patients with cancer. We are developing transformational cancer immunotherapies for patients who have few remaining options.
FundersClub focuses on Seed and early stage investments. Investments include Coinbase, Instacart, Flexport, Le Tote, Teespring, Memebox, GitLab.FundersClub is the world's first online venture capital platform. Backed by Y Combinator, First Round Capital, Spark Capital, Intel Capital, Draper, Andreessen Horowitz, Felicis Ventures, and more;FundersClub Inc. was founded in 2012 and is based in the United States.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, SaaS
- Stage:Seed, Series A, Pre-Seed
- Geography: United States, Canada, India
Investor stats
- Total investments: 550
- Round size: Seed $668k–$5M; Pre-Seed $125k–$1.7M; Series A $3M–$23M
- Lead/follow: 4% lead, 96% follow
- Last fund: Likely still investing — raised $120k in 2024
Portfolio highlights
- Klaimee — Financial protection for companies building or using AI agents. Understand covered failures, explore pricing, and start your agent risk assessment.
- Scape — Scape is an AI email client that proactively drafts replies and surfaces what matters. Built for professionals who live in their inbox.
- Numeral — We fully manage the headaches of sales tax so you can get back to real work. Get started for free today!
Targeting critical European re-industrialisation technology across pioneering hardware sectors with capital efficient growth investments.
Show more...Investment focus
- Industry: Energy, Energy Storage, Renewable Energy
- Stage:Venture - Series Unknown, Seed
- Geography: Denmark, Germany, Sweden
Investor stats
- Total investments: 29
- Round size: Seed $3M–$8.7M; Venture - Series Unknown $4.5M–$9.8M
- Lead/follow: 72% lead, 28% follow
- Last fund: Likely still investing — raised $286M in 2024
Portfolio highlights
- Stabl Energy — Scalable battery storage systems for energy storage in industry and commerce made by STABL Energy help to utilise the full potential of renewable energies.
- Green Hydrogen Systems — GreenHydrogen believes that electrolysers have a great potential to become a core technology in green and renewable energy.
- Hybrid Greentech — Hybrid Greentech offers end-to-end profitable solutions for BESS projects, from detailed business case and sizing analysis to project development services, EPC management, and operations and optimization for multi-market revenue stacking.
The Yield Lab Europe is a €55m early stage Agrifood and Ag Tech fund which comprises an accelerator and a larger follow-on fund, investing in high tech companies with the potential to significant disrupt and improve our current systems of global food production, and to improve the environmental sustainability of the industry. The main fund invests€1m each into 10-12 companies over several follow on rounds, with the strongest accelerator companies expected to progress to the main fund. The Yield Lab Europe is also part of a global network of Agrifood Tech funds, with global headquarters in St Louis USA, and sister funds in LATAM and Singapore.
Show more...Investment focus
- Industry: AgTech, Agriculture, Biotechnology
- Stage:Seed, Series A, Venture - Series Unknown
- Geography: Ireland, France, United Kingdom
Investor stats
- Total investments: 40
- Round size: Seed $605k–$2.9M; Series A $2.1M–$10M; Venture - Series Unknown $1.7M–$9.6M
- Lead/follow: 35% lead, 65% follow
- Last fund: May invest from a new fund soon — raised $67M in 2021
Portfolio highlights
- BBLeap — Farming On Plant Level - We are BBLeap and we are going to create a LEAP in Agriculture! Enabling you to spray exactly what you want. No more, no less!
- BiOceanOr — BiOceanOr harnessed the power of Marine Biology and AI to deliver bio-guided services that optimize fish welfare and fish growth, while supporting aquaculture sustainability standards
- Marama Labs — Marama Labs is a developer of a novel UV-Vis spectroscopy technology for scientific-analytical instrumentation. It assists customers in identifying and measuring turbid samples' characteristics by using light's spectral properties. It offers an ultra-violet and visible spectrophotometer for measuring absorption, extinction, and scatteringspectra of clear and turbid liquids to help customers keep their samples intact, reduce sample preparation steps, and improve measurement turnaround time.
byFounders is the community-powered early-stage venture fund investing in globally ambitious teams connected to the Nordic and Baltic countries. With its unique Collective of founders and operators, byFounders offers its portfolio operational expertise and a global network. Believing in the power of tech to shape our future, byFounders takes an impact-aware approach to investing and working with the broader startup ecosystem.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, SaaS
- Stage:Seed, Pre-Seed, Series A
- Geography: Denmark, United States, Sweden
Investor stats
- Total investments: 135
- Round size: Seed $1.5M–$9.4M; Pre-Seed $750k–$4.3M; Series A $6.1M–$65M
- Lead/follow: 50% lead, 50% follow
- Last fund: May invest from a new fund soon — raised $130M in 2021
Portfolio highlights
- Fluencify — Fluencify is an innovative creator marketing platform that runs end to end user generated content programs for global brands. The software powered solution enforces brand quality guidelines, handles global creator payments, and provides contracted view guarantees to turn influencer marketing into a scalable utility framework.
- Verda — Verda provides a full-stack AI cloud platform for the development, training, and deployment of AI models.
- Cota Robotics — Cota Robotics deploys general-purpose robots in retail stores through a Robot-as-a-Service model, integrating with existing environments without requiring changes to store layouts or infrastructure. The company automates shelf replenishment, inbound handling, and order picking using human-in-the-loop teleoperation, with autonomy increasing asdeployment data trains its models.
Giampaolo’s aim has always been to apply a disruptive approach to functional food ingredients and that’s how he founded Italiana Ingredienti in ’89 and Campus in ’05. Both companies have been acquired, Italiana Ingredienti by Chr. Hansen in ‘99 and Campus by Firmenich in ’18. Today he serves as Founder and Chairman at Hi-Food, an Italian companyproviding key functional ingredients to food companies, and as a business Angel Investor in several startups.
Show more...Investment focus
- Industry: Chemical, Biotechnology, Food and Beverage
- Stage:Seed, Pre-Seed
- Geography: Italy, Denmark
Investor stats
- Total investments: 3
- Round size: Seed $4.9M–$7.6M
- Lead/follow: 33% lead, 67% follow
Portfolio highlights
- Chromologics — Chromologics produce natural sustainable colors. Our flagship product is ChromoRed which performs better than existing natural, red colorants. ChromoRed is also applicable with vegan, kosher and halal diets.
- Dreamfarm — We are a team of food-lovers 100% made in Italy! We dreamt of a better, tastier, more sustainable future and decided to join forces to create something special.
Biotechnology Investor funding in Denmark at a glance
Stats across 387 deals from 360 investors.
Access all 360 investors in Denmark Biotechnology startups.
Open ListFAQ
Is Shizune data fresh/accurate?
Shizune has monitored hundreds of funding sources since 2020.
Our investor database is updated every day, so investor data is always fresh.
All metrics are calculated from confirmed public rounds, so the data is accurate.
Can I download investor list?
To download the Biotechnology Investors in Denmark investor list, create a Shizune account. This investor list will be added to your saved investors and available for download in the export section.
You can also enrich the investor list with investor emails, phones, LinkedIns, and other contact data.
Can I access investor database?
To access all 360 investors investing in Denmark Biotechnology startups and 48,091+ more investors, create a Shizune account.
Shizune has a database of 48,091 investors. Our investor database is fresh and updated daily.
The Shizune investor database has information on investor investment focus, investor contact data, and full investor portfolio since 2020.
You can enrich with email and download the data.
Does Shizune have investor emails and contacts?
Shizune enriches investors with contact data that includes: email, phones, LinkedIn, socials, website, and others.
To guarantee the highest discovery rate, we search across 20+ contact search tools.
To maximize delivery rate and reduce bounce rate, we validate emails.
You can enrich your investor list with Shizune. Download it too.
What is Shizune?
Shizune is a 48,091 investor database updated daily.
With Shizune you can:
- browse the database
- use smart matching
- enrich with emails
- download
All you need to find investors for your startup.
Who is Shizune for?
Shizune is built for startup founders by startup founders.
If you are looking for funding for your startup, try the Shizune database — we have investors for every stage, industry, and country.
Is Shizune free?
Shizune is free forever. You can search and browse investors for free.
Email search and export are paid features.
For full info, visit our pricing.
Who built Shizune?
Shizune is built by founders with the goal of helping all founders raise funding no matter where they are.
Contact 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!